8/102 sources · 2 publishersUpdated Oct 28, 01:49 UTC
Beta Bionics posts record Q3 revenue, FDA clears Mint pump and raises 2026 guidance
Beta Bionics reported third‑quarter 2026 net sales of $35.5 million, a 30% year‑over‑year increase, but posted a net loss of $24.4 million and adjusted EPS of –$0.52. The company received FDA clearance for its Mint patch insulin pump in September 2026 and plans a U.S. commercial launch in the first quarter of 2027. Management raised full‑year 2026 revenue guidance to a range of $124 million‑$126 million.
Why it matters
The higher revenue guidance signals stronger top‑line momentum for the year, while the Mint launch could expand the product portfolio and improve future cash flows, according to the company’s guidance update ().
Key facts
- 1Q3 2026 net sales were $35.5 million, up 30% YoY. investing.com
- 2The quarter generated a net loss of $24.4 million. investing.com
- 3Adjusted EPS for the quarter was –$0.52. investing.com
- 4The FDA cleared Beta Bionics’ Mint patch pump in September 2026. investing.com
- 5Full‑year 2026 revenue guidance was raised to $124 million‑$126 million. investing.com
- 6Mint is slated for U.S. commercial launch in Q1 2027. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.